SCHEDULE: Seven Fleet Discloses 0.02% Stake in CytomX Therapeutics
Beneficial Ownership Report
Seven Fleet Master Fund LP and its affiliates reported a 0.02% beneficial ownership stake in CytomX Therapeutics, Inc. as of September 30, 2025.
Summary
- Seven Fleet Master Fund LP, Seven Fleet Capital Management LP, Seven Fleet Capital Management GP LLC, and Brian Liu (collectively, the "Reporting Persons") filed a Schedule 13G.
- The Reporting Persons beneficially own an aggregate of 48,898 shares of CytomX Therapeutics, Inc. Common Stock.
- This ownership represents 0.02% of the 169,435,395 shares of Common Stock outstanding as of September 30, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on November 6, 2025.
- All beneficially owned shares are held of record by Seven Fleet Master Fund LP, with shared voting and dispositive power attributed to Seven Fleet Capital Management LP, Seven Fleet Capital Management GP LLC, and Brian Liu due to their management roles.
- The filing notes that Longitude Capital Management Co. LLC may be deemed to beneficially own 11,538,461 shares, constituting 6.8% of the outstanding Common Stock, but the Reporting Persons expressly disclaim group membership and beneficial ownership over any shares held by Longitude.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing disclosing beneficial ownership below the 5% threshold, with no direct positive or negative implications for the issuer's operational or financial performance.
Future Outlook
NA
Industry Context
NA
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event requiring the filing of this statement (beneficial ownership calculation date). |
| 11/06/2025 | Date CytomX Therapeutics, Inc. filed its Quarterly Report on Form 10-Q, reporting 169,435,395 shares outstanding. |
| 11/14/2025 | Date the Schedule 13G was signed and filed by the Reporting Persons. |
Keywords
CytomX Therapeutics, CTMX, Schedule 13G, Beneficial Ownership, Seven Fleet Master Fund, Investment, Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.